THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE PROHIBITED BY ANY APPLICABLE LAW.
Mereo BioPharma Group plc
("Mereo" or the "Company") (AIM: MPH)
Successful Completion of PrimaryBid Offer
Mereo BioPharma Group plc (AIM: MPH), announced on 25 May 2018 the launch of an offer via PrimaryBid (the “Offer”) to broaden its shareholder base by accessing additional retail investors via the Offer.
The Company has placed 50,076 ordinary shares of 0.3 pence each (“Ordinary Shares”) via PrimaryBid at 300p per Ordinary Share. The Company will allot and issue 50,076 new Ordinary Shares ("New Ordinary Shares") pursuant to the Offer. Application will be made for the New Ordinary Shares to be admitted to trading on AIM, which is anticipated to occur on or around 1 June 2018 ("Admission"). The New Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.
Total Voting Rights
Following Admission, the Company will have 71,145,050 Ordinary Shares in issue with voting rights. The Company does not hold any Ordinary Shares in treasury and accordingly there are no voting rights in respect of any treasury shares. Therefore, the total number of voting rights in the Company with effect from Admission will be 71,145,050. This figure may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
Mereo BioPharma Group plc +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer
Cantor Fitzgerald Europe (Nominated Adviser) +44 (0)20 7894 7000
Dave Mutton +44 (0)20 7491 6519
FTI Consulting (Public Relations Adviser)
Simon Conway +44 (0)20 3727 1000
The person responsible for arranging the release of this information on behalf of the Company is Charles Sermon, Company Secretary.